Swiss Stock News

Logitech International (SWX:LOGN) has introduced its Rally AI Camera and Rally AI Camera Pro, two AI-powered conference cameras. The new products focus on room usage detection, sustainability features, and integration into managed network environments. The launch marks an expansion of Logitech's video collaboration portfolio aimed at enterprise and education customers. For Logitech, known for its peripherals and video collaboration gear, the Rally AI Camera line extends its presence in...

Partners Group’s new special opportunities push Partners Group Holding (SWX:PGHN) has launched a global special opportunities strategy targeting liquidity driven situations worldwide. The strategy is led by new partner Joshua Hartz and expands the firm’s existing multi strategy private markets platform. See our latest analysis for Partners Group Holding. Partners Group Holding’s CHF1,082.50 share price follows a 10.87% 30-day share price return and 8.55% 90-day share price return. However,...

While SIG Group AG ( VTX:SIGN ) might not have the largest market cap around , it led the SWX gainers with a relatively...

As of January 2026, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by 0.77%, buoyed by strong economic data and earnings results. In this context of mixed performance across major indices like Germany's DAX and France's CAC 40, identifying stocks that may be trading below their estimated value involves looking for companies with solid fundamentals that could benefit from ongoing economic recovery and favorable trade conditions.

As the European market shows resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are increasingly drawn to dividend stocks for their potential to provide steady income in uncertain times. In this context, selecting a good dividend stock involves considering factors like consistent payout history and financial stability, which can offer a buffer against market volatility.

Galderma Group (SWX:GALD) is back in focus after announcing fresh clinical and real world data for its neuromodulators Relfydess and Dysport at the TOXINS 2026 International Conference in Madrid. See our latest analysis for Galderma Group. The fresh neuromodulator data arrives after a softer near term patch for the stock, with a 30 day share price return of 5.53% and a 7 day share price return of a 3.21% decline, even though the 90 day share price return is 12.84% and the 1 year total...

In mid-January 2026, Novartis reported that the US FDA granted Breakthrough Therapy designation to ianalumab for Sjögren’s disease, a fully human monoclonal antibody with a dual B‑cell and BAFF‑R blockade mechanism supported by positive replicate Phase III data. This move positions ianalumab as a potential first targeted therapy in a condition with no approved targeted treatments, highlighting Novartis’s growing focus on complex autoimmune diseases and late-stage specialty medicines. We’ll...

In January 2026, Chocoladefabriken Lindt & Sprüngli AG issued earnings guidance indicating it expects its 2025 operating profit margin to rise at the lower end of a 20–40 basis point improvement range from the previous year’s 16.2%. The company also projected ongoing annual operating margin improvements of 20–40 basis points from 2026 onwards, underscoring a clear emphasis on gradual profitability enhancement. We will now examine how Lindt & Sprüngli’s focus on steady operating margin...

If you are wondering whether Logitech International's current share price still lines up with its fundamentals, you are not alone. The stock recently closed at US$72.48, with returns of a 6.0% decline over 7 days, a 12.7% decline over 30 days, an 8.8% decline year to date, a 9.6% decline over 1 year, a 40.9% return over 3 years, and a 13.7% decline over 5 years, which can change how investors think about both opportunity and risk. Recent coverage has highlighted Logitech International in...

Sandoz Group (SWX:SDZ) is back in focus after the European Commission granted marketing authorization for Ondibta, a biosimilar insulin glargine that could widen diabetes treatment options across Europe from early 2027. See our latest analysis for Sandoz Group. The Ondibta news lands after a strong 90 day share price return of 27.17% and a 1 year total shareholder return of 49.84%, suggesting momentum has been building around Sandoz Group, despite a 1 day share price return decline of 0.75%...

The Ascom Holding AG ( VTX:ASCN ) share price has done very well over the last month, posting an excellent gain of 32...

Helvetia Baloise Holding (VTX:HBAN) has had a rough month with its share price down 3.7%. But if you pay close...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 20x, you may consider...

It's not a stretch to say that Swiss Life Holding AG's ( VTX:SLHN ) price-to-earnings (or "P/E") ratio of 20.8x right...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 20x, you may consider...

Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high...

While not a mind-blowing move, it is good to see that the Temenos AG ( VTX:TEMN ) share price has gained 23% in the...

Let's talk about the popular Kuehne + Nagel International AG ( VTX:KNIN ). The company's shares saw a significant share...

As the European market shows resilience with the STOXX Europe 600 Index rising by 0.77% amid solid economic data and earnings results, investors are increasingly focusing on dividend stocks to bolster their portfolios. In a climate where stability and income generation are highly valued, selecting dividend stocks that align with robust financial performance and consistent payout histories can be a prudent strategy for enhancing investment portfolios.

Schindler Holding AG ( VTX:SCHN ) saw a double-digit share price rise of over 10% in the past couple of months on the...

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...

ARYZTA AG's ( VTX:ARYN ) price-to-earnings (or "P/E") ratio of 12.8x might make it look like a buy right now compared...

Despite an already strong run, Comet Holding AG ( VTX:COTN ) shares have been powering on, with a gain of 33% in the...

Why Cosmo Pharmaceuticals is Back on Investors’ Radars Cosmo Pharmaceuticals (SWX:COPN) is drawing fresh attention after management detailed a scale up phase under its Vision 2030 plan, highlighting solid finances, expanding GI Genius and Winlevi franchises, and a maturing dermatology and gastroenterology pipeline. See our latest analysis for Cosmo Pharmaceuticals. That story around Vision 2030 seems to be resonating with the market, with a 90 day share price return of 75.23% and a 1 year...